412 an Emollient Attenuates the Progression of Cognitive Impairment in the Elderly

L. Ye,Z. Wang,Y. Kim,P. M. Elias,T. Li,S. Wen,J. Song,B. Yang,C. Lv,M. Man
DOI: https://doi.org/10.1016/j.jid.2022.05.421
IF: 7.59
2022-01-01
Journal of Investigative Dermatology
Abstract:Cognitive impairment (CI) is common in the elderly. Prior studies suggest a link between chronic inflammation and CI. Additionally, an age-associated increase in cutaneous cytokines has been connected to elevated circulating cytokines. We therefore assessed here whether topical emollient can mitigate the progression of CI. Methods: This randomized, open-label pilot trial was carried out in Dalian and Shenyang, in northern China. Eligible participants were ≥65 years old and were randomly assigned to the treated and untreated groups at 1:1 ratio. The treated group were treated topically with Atopalm cream® twice-daily from November to the following May each year for three consecutive years, while the untreated subjects served as controls. The Global Deterioration Scale (GDS) was used to assess the severity of CI in November and the following May of each year, while epidermal biophysical properties were measured on the forearms and the shins. Results: A total of 200 eligible participants, including 63 males and 137 females, aged 75.83 ± 0.62 years were enrolled. Over the 3-year trial, GDS increased significantly in the controls, while in the treated group, GDS remained stable. While stratum corneum hydration (SCH) on the forearms did not change significantly in the controls, transepidermal water loss rates (TEWL), significantly increased by the end of the trial compared to baselines in the controls. Skin surface pH declined slightly in the controls. On the forearms of the treated group, SCH increased significantly, while surface pH markedly decreased. TEWL was comparable before and after the trial. These results demonstrate that improvements in epidermal function can mitigate the progression of CI. However, the sample size was relatively small, and trials in a larger cohort are needed to validate the present results.
What problem does this paper attempt to address?